Actinium Pharmaceuticals Inc. Highlights Promising Preclinical Data for Actimab-A in AML Treatment
New York, April 28, 2025 — Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), a clinical-stage biopharmaceutical company based in New York, announced significant preclinical findings for its lead product candidate, Actimab-A, at the American Association for Cancer Research (AACR) Annual Meeting. The data presented underscore Actimab-A’s potential as a mutation agnostic therapy for acute myeloid leukemia (AML).
Actimab-A, a CD33 targeted radiotherapy utilizing the Actinium-225 isotope, demonstrated potent antileukemic activity in preclinical AML models. The therapy showed efficacy against various mutations, including FLT3, NPM1, KMT2A, and TP53, which are commonly associated with AML. The combination of Actimab-A with standard care therapies, such as the hypomethylating agent azacitidine and FLT3 and menin inhibitors, significantly enhanced and prolonged antileukemic effects in in-vivo AML models.
Actinium Pharmaceuticals is advancing Actimab-A through several combination studies. Notably, a Phase 2/3 trial is underway in combination with CLAG-M for relapsed/refractory AML. Additionally, Actimab-A is being tested with Venetoclax and ASTX-727, an oral hypomethylating agent from Taiho Oncology, in frontline AML under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI).
Investor Alert: Legal Investigation into Actinium Pharmaceuticals
April 26, 2025 — Faruqi & Faruqi, LLP has initiated an investigation on behalf of investors concerning Actinium Pharmaceuticals, Inc. The investigation follows concerns raised by investors regarding the company’s financial and operational practices. This development may impact investor confidence and the company’s stock performance.
Legal Support for Actinium Pharmaceuticals
April 25, 2025 — ROSEN, a leading law firm, has expressed support for Actinium Pharmaceuticals, Inc. amid ongoing investor concerns. The firm’s involvement aims to address and resolve any legal issues that may arise from the current investor investigation.
Company Overview
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody radiation conjugates for targeted conditioning and combination therapies. The company’s mission is to revolutionize treatment approaches through innovative biotechnological advancements. Actinium Pharmaceuticals serves clients exclusively in the United States and is listed on the New York Stock Exchange American.
Financial Snapshot
- Close Price (April 24, 2025): $1.31
- 52 Weeks High (May 13, 2024): $10.24
- 52 Weeks Low (March 3, 2025): $1.029
- Market Cap: $39,620,000
- Price Earnings Ratio: -0.997228
For more information, visit Actinium Pharmaceuticals’ website .